A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine

Vaccine

Volumn 29, Issue 27, 2011, Pages 4485-4491

  Haralambieva, Iana H ^a   Ovsyannikova, Inna G ^a   O'Byrne, Megan ^a   Pankratz, V Shane ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cellular immunity; Measles; Neutralizing antibodies; Plaque reduction microneutralization; Vaccine

Indexed keywords

GAMMA INTERFERON; MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INFANT; MALE; MEASLES; NORMAL HUMAN; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PLAQUE REDUCTION MICRONEUTRALIZATION ASSAY; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION; WILD TYPE;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; CHILD; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; MALE; MEASLES; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; NEUTRALIZATION TESTS; PLAQUE ASSAY; T-LYMPHOCYTES; YOUNG ADULT;

EID: 79958164976     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.037     Document Type: Article

References (53)

1. Progress in global measles control and mortality reduction, 2000-2007. MMWR Morb Mortal Wkly Rep 2008;57(48):1303-6.
2. Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep 2009;58(47):1321-6.
3. Plemper R.K., Snyder J.P. Measles control-can measles virus inhibitors make a difference?. Curr Opin Investig Drugs 2009, 10(8):811-820.
4. Sugerman D.E., Barskey A.E., Delea M.G., Ortega-Sanchez I.R., Bi D., Ralston K.J., et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 2010, 125(4):747-755.
5. Jick H., Hagberg K.W. Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine 2010, 28(29):4588-4592.
6. Kennedy A.M., Gust D.A. Measles outbreak associated with a church congregation: a study of immunization attitudes of congregation members. Public Health Rep 2008, 123(2):126-134.
7. Measles-United States, January 1-April 25, 2008. MMWR Morb Mortal Wkly Rep 2008;57(18):494-8.
8. Albrecht P., Herrmann K., Burns G.R. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981, 3(5):251-260.
9. Ratnam S., Gadag V., West R., Burris J., Oates E., Stead F., et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995, 33(4):811-815.
10. Cohen B.J., Parry R.P., Doblas D., Samuel D., Warrener L., Andrews N., et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 2006, 131(2):209-212.
11. Cohen B.J., Audet S., Andrews N., Beeler J. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007, 26(1):59-66.
12. Cohen B.J., Parry R.P., Andrews N., Bennett A.M., Dennis J.H. Laboratory methods for assessing vaccine potency retained in aerosol outputs from nebulizers: application to World Health Organization measles aerosol project. Vaccine 2008, 26(27-28):3534-3539.
13. Haralambieva I.H., Ovsyannikova I.G., Vierkant R.A., Poland G.A. Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles immunity. Clin Vaccine Immunol 2008, 15(7):1054-1059.
14. Thio C.L., Thomas D.L., Goedert J.J., Vlahov D., Nelson K.E., Hilgartner M.W., et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001, 184(1):16-21.
15. Mayr F.B., Spiel A.O., Leitner J.M., Firbas C., Kliegel T., Jilma B. Ethnic differences in plasma levels of interleukin-8 (IL-8) and granulocyte colony stimulating factor (G-CSF). Transl Res 2007, 149(1):10-14.
16. Hoffmann S.C., Stanley E.M., Cox E.D., DiMercurio B.S., Koziol D.E., Harlan D.M., et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002, 2(6):560-567.
17. Zabaleta J., Schneider B.G., Ryckman K., Hooper P.F., Camargo M.C., Piazuelo M.B., et al. Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development. Cancer Immunol Immunother 2008, 57(1):107-114.
18. de la C.S., Kouri G., Guzman M.G. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 2007, 152(3):533-542.
19. Dhiman N., Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., Jacobson R.M., Poland G.A. Associations between cytokine/cytokine receptor SNPs and humoral immunity to measles, mumps and rubella in a Somali population. Tissue Antigens 2008, 72(3):211-220.
20. Dhiman N., Haralambieva I.H., Vierkant R.A., Pankratz V.S., Ryan J.E., Jacobson R.M., et al. Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in health vaccinees. Cytokine 2010, 50:24-29.
21. Klein N.P., Holmes T.H., Sharp M.A., Heineman T.C., Schleiss M.R., Bernstein D.I., et al. Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine 2006, 24(33-34):5913-5918.
22. Green M.S., Shohat T., Lerman Y., Cohen D., Slepon R., Duvdevani P., et al. Sex differences in the humoral antibody response to live measles vaccine in young adults. Int J Epidemiol 1994, 23(5):1078-1081.
23. Mitchell L.A. Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation. J Med Microbiol 1999, 48(12):1075-1080.
24. Dominguez A., Plans P., Costa J., et al. Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study. Eur J Clin Microbiol Infect Dis 2006, 25(5):310-317.
25. Ovsyannikova I.G., Jacobson R.M., Dhiman N., Vierkant R.A., Pankratz V.S., Poland G.A. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008, 121(5):e1091-e1099.
26. Kennedy R., Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., Ryan M.A., et al. Gender effects on humoral immune response to smallpox vaccine. Vaccine 2008, 27:3319-3323.
27. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26(29-30):3551-3555.
28. Atabani S., Landucci G., Steward M.W., Whittle H., Tilles J.G., Forthal D.N. Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines. Clin Diagn Lab Immunol 2000, 7(1):111-113.
29. Ryan J.E., Ovsyannikova I.G., Dhiman N., Pinsky N.A., Vierkant R.A., Jacobson R.M., et al. Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma secreting T cells. Scand J Clin Lab Invest 2005, 65(8):681-690.
30. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990, 162(5):1036-1042.
31. Ratnam S., Gadag V., West R., Burris J., Oates E., Stead F., et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995, 33:811-815.
32. Ward B.J., Aouchiche S., Martel N., Bertley F.M., Bautista-Lopez N., Serhir B., et al. Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. Diagn Microbiol Infect Dis 1999, 33(3):147-152.
33. Hesketh L., Charlett A., Farrington P., Miller E., Forsey T., Morgan-Capner P. An evaluation of nine commercial EIA kits for the detection of measles specific IgG. J Virol Methods 1997, 66(1):51-59.
34. Bouche F.B., Ertl O.T., Muller C.P. Neutralizing B, cell response in measles. Viral Immunol 2002, 15(3):451-471.
35. McQuillan G.M., Kruszon-Moran D., Hyde T.B., Forghani B., Bellini W., Dayan G.H. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis 2007, 196(10):1459-1464.
36. LeBaron C.W., Beeler J., Sullivan B.J., Forghani B., Bi D., Beck C., et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007, 161(3):294-301.
37. Mossong J., Nokes D.J., Edmunds W.J., Cox M.J., Ratnam S., Muller C.P. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 1999, 150(11):1238-1249.
38. Christenson B., Böttiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994, 12:129-133.
39. Ratnam S., West R., Gadag V., Williams B., Oates E. Immunity against measles in school-aged children: implications for measles revaccination strategies. Can J Public Health 1996, 87(6):407-410.
40. Samb B., Aaby P., Whittle H.C., Seck A.M., Rahman S., Bennett J., et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995, 14(3):203-209.
41. Ward B.J., Boulianne N., Ratnam S., Guiot M.C., Couillard M., De Serres G. Cellular immunity in measles vaccine failure: Demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995, 172:1591-1595.
42. Markowitz L.E., Albrecht P., Orenstein W.A., Lett S.M., Pugliese T.J., Farrell D. Persistence of measles antibody after revaccination. J Infect Dis 1992, 166(1):205-208.
43. Orenstein W.A., Albrecht P., Herrmann K.L., Bernier R., Bart K.J., Rovira E.Z. The plaque-neutralization test as a measure of prior exposure to measles virus. J Infect Dis 1987, 155(1):146-149.
44. Gans H., Yasukawa L., Rinki M., DeHovitz R., Forghani B., Beeler J., et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001, 184(7):817-826.
45. Gans H.A., Yasukawa L.L., Alderson A., Rinki M., DeHovitz R., Beeler J., et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004, 190(1):83-90.
46. Update: multistate outbreak of mumps-United States, January 1-2May, 2006. MMWR Morb Mortal Wkly Rep 2006;55(20):559-63.
47. Poland G.A., Jacobson R.M., Colbourne S.A., Thampy A.M., Lipsky J.J., Wollan P.C., et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 1999, 17:1525-1531.
48. Sauver J.L., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Green E.M., Poland G.A. Association of parental vaccination reports with measles, mumps, and rubella protective antibody levels: comparison of Somali immigrant, Hispanic migrant, and US children in Rochester, Minn. Mayo Clin Proc 2002, 77:241-245.
49. Johnson C.E., Kumar M.L., Whitwell J.K., Staehle B.O., Rome L.P., Dinakar C., et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996, 15(8):687-692.
50. Mossong J., O'Callaghan C.J., Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 2000, 19(4-5):523-529.
51. Pebody R.G., Gay N.J., Hesketh L.M., Vyse A., Morgan-Capner P., Brown D.W., et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002, 20:1134-1140.
52. Poland G.A., Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001, 20(3-4):430-438.
53. Shohat T., Green M.S., Nakar O., Ballin A., Duvdevani P., Cohen A., et al. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Isr Med Assoc J 2000, 2:192-195.